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ABSTRACT
Pouchitis is the most common complication following 
proctocolectomy with ileal pouch-anal anastomosis for ulcerative 
colitis (UC). To provide a standardized definition of pouchitis 
clinical, endoscopic and histological markers were grouped and 
weighted in the pouch disease activity index (PDAI). However, the 
delay in the assessment of the final score due to the time requested 
for histological analysis remains the main obstacle to the index 
implementation in clinical practice so that the use of modified-
PDAI (mPDAI) with exclusion of histologic subscore has been 
proposed. We tested the ability of calprotectin measurement in 
the pouch endoluminal content to mimic the histologic score as 
defined in the PDAI, the index that we adopted as gold standard 
for pouchitis diagnosis. Calprotectin was measured by ELISA in 
the pouch endoluminal content collected during endoscopy in 
40 consecutive patients with J-pouch. In each patient PDAI and 
mPDAI were calculated and 15% of patients were erroneously 
classified by mPDAI. ROC analysis of calprotectin values vs. acute 
histological subscore ≥ 3 identified different calprotectin cut-off 
values with corresponding sensitivity and specificity allowing the 
definition and scoring of different range of calprotectin subscores. 
We incorporated the calprotectin score in the mPDAI obtaining a 
new score that shows the same specificity as PDAI for diagnosis of 
pouchitis and higher sensitivity when compared with mPDAI. The 
use of the proposed new score, once validated in a larger series of 
patients, might be useful in the early management of patients with 
symptoms of pouchitis.
Key words: Pouchitis. Calprotectin. Ulcerative colitis. Disease 
activity index.
INTRODUCTION 
Restorative proctocolectomy with ileal pouch-anal 
anastomosis (IPAA) is the surgical treatment of choice 
for patients with ulcerative colitis (UC). Pouchitis, a 
non-specific, idiopathic inflammation of the ileal reser-
voir, is the most common complication following surgery 
for UC (1-3). The reported incidence of pouchitis var-
ies because of the different diagnostic criteria employed 
(4,5). To standardize the definition and assess the severity 
of pouchitis, diagnosis should be made on the basis of 
clinical, endoscopic, and histological criteria. Pouchitis 
disease activity index (PDAI), as proposed by Sandborn 
et al., represents an objective and reproducible scoring 
system in which endoscopic and histological evaluation 
together with symptom assessment independently con-
tribute to diagnose pouchitis (6). The role of histology in 
pouchitis diagnosis has been debated (7). In addition, the 
delay in the assessment of the final score due to the time 
requested for histological analysis, the high cost of this 
procedure as well as the need of an experienced pathol-
ogist remain the main obstacle to its implementation in 
clinical practice. A simplified approach to the diagnosis 
of pouchitis with the use of modified pouchitis disease 
activity index (mPDAI) that takes into account symptoms 
and endoscopy with exclusion of histological score has 
been proposed (8).
Fecal calprotectin measurement has been demonstrat-
ed to be a useful non-invasive tool in the diagnosis of 
inflammatory bowel disease (9-12). Recently fecal calpro-
tectin measurement has been also investigated in acutely 
inflamed ileal pouches and showed to correlate closely 
with the Objective Pouchitis Score, the PDAI as well as 
with endoscopic and histological inflammatory subscores 
(13). Moreover, it appears that elevated faecal calprotectin 
levels are significant predictors of pouchitis (14). On this 
basis, monitoring of faecal calprotectin has been proposed 
in the follow up of patients with IPAA. However, it is gen-
erally accepted that laboratory findings should not replace 
pouch endoscopy as first-line evaluation method (15). 
In the present study, we evaluated the contribution of 
calprotectin measurement to the diagnosis of pouchitis 
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assessed with PDAI. To make the whole process more 
accessible to the patient and the analyst we integrated the 
collection of the sample for calprotectin measurement in 
the pouch endoscopy procedure by collection of the pouch 
endoluminal content.
MATERIALS AND METHODS
We carried out an observational cross-sectional study on patients 
who underwent restorative proctocolectomy with J-pouch IPAA for 
UC at the Department of General Surgery “P. Stefanini”, Sapien-
za University, Rome. Patients with original indications to IPAA 
other than UC, pouch conformation other than J, or patients who 
were treated with antibiotic, immunomodulating agents, steroids or 
non-steroidal anti-inflammatory drugs in the previous 3 months, or 
who were treated with antiplatelet or anticoagulant medicinal prod-
ucts in the previous 2 weeks were excluded from the study 
Patients eligible for the study underwent clinical assessment and 
endoscopic examination of the ileal pouch in the same day.
Clinical assessment
Patients were interviewed using a structured form, and symptom 
score for PDAI/mPDAI was calculated. The criterion used to define 
the existence of pouchitis was a PDAI ≥ 7.
Endoscopy
Pouchscopy was performed by a single experienced endoscopist. 
All patients underwent a pouch enema (Sorbiclis®) from 4 to 2 hours 
before pouchscopy. All pouchscopies were performed by flexible 
fine endoscope (Olympus®). Pouchscopy included macroscopic 
exploration of the entire pouch, afferent ileum within 15 cm and 
the anal canal. Mucosal appearance abnormalities, particularly the 
specific acute macroscopic inflammatory features for PDAI score 
calculation (edema, granularity, friability, loss of vascular pattern, 
mucus exudate, ulceration) were recorded and scored as 1 each when 
present. Final endoscopic score was annotated by the endoscopist, 
who was blinded to the clinical data.
Multiple biopsies (n = 8-12) were taken from the upper and lower 
pouch. Biopsies were fixed in 10% buffered formalin and send to 
the histopathology section.
Histology
Specimens, after processing, were scored according to Shep-
herd-Moskowitz
 
classification (16) and finally scored from 0 to 
6 using Sandborn‘s criteria for PDAI (6) by the pathologist, who 
was blinded to the clinical and endoscopic data. For the purpose of 
the present investigation a histological subscore ≥ 3 indicates the 
presence of histological pouchitis. Data from clinical, endoscopic 
and histological subscores were finally added to obtain PDAI score, 
while mPDAI was calculated on the basis of clinical and endoscopic 
subscores only. 
Pouch endoluminal content sample collection and 
calprotectin measurement
Immediately after scope insertion, a sample of 3-5 ml of pouch 
endoluminal content was collected by aspiration with endoscope 
and retrieved in a basket trap (Endo-technik®). It was then trans-
ferred in a screw cap test tube and delivered at room temperature 
to the laboratory within 4 hours after collection. Each sample was 
centrifuged at 4,000 rpm for 10 minutes at room temperature; the 
clear extract supernatant was collected and transferred to an Eppen-
dorf tube labeled with the patient’s code, and immediately frozen 
and stored at -30 °C for subsequent calprotectin measurement. After 
thawing serial dilutions of each sample were performed using the 
dilution buffer provided in the kit, and calprotectin was measured by 
ELISA using Calprest Test® (Eurospital, Trieste, Italy).
Statistical analysis
Statistical analysis was performed using the statistical package 
GraphPad® Prism 5 (San Diego, CA, USA). Results of numerical data 
are presented as mean ± standard deviation (SD) or median and range, 
with a 95% confidence interval (CI) when appropriate. Statistically 
significant differences between median values were determined using 
the Mann-Whitney U test. The Spearman rank test or Pearson correla-
tion test were used to determine the degree of correlation, as appro-
priate. The receiver operating characteristic curve (ROC) was used 
to predict the sensitivity and specificity of fecal calprotectin for the 
prediction of PDAI- defined pouchitis and the acute histological score.
Ethical considerations
All procedures complied with the principles of the Declaration 
of Helsinki. Patients were provided with detailed information about 
the study aims and gave their written, informed consent.
RESULTS
Forty consecutive patients attending the department for 
routine clinical and endoscopic surveillance from Septem-
ber 2013 to September 2014 who underwent restorative 
proctocolectomy with J- pouch IPAA for UC were recruit-
ed in the study. In 6 patients the IPAA was performed at the 
dentate line by hand-sewn transanal suture after mucosec-
tomy. In 34 patients stapled IPAA without mucosectomy 
was performed at level of transitional zone at an average 
distance of 0.5 cm from the dentate line. The employed 
technique minimizes the risk of residual rectal mucosa and 
development of cuffitis. All patients were in early-medi-
um and long-term follow-up. Characteristics of patients 
included in the study were as follows: male/female: 20/20; 
age of patients: 52 (33-71) years, median (range); age of 
pouch: 127 (3-307) months, median (range); quality of life 
score (QoL) (0-87): 23 (1-62), median (range); number of 
patients with history of pouchitis: 20 (episodic: 10; antibi-
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otic-sensitive recurrent pouchitis: 6; antibiotic-dependent 
chronic pouchitis: 2; chronic resistant pouchitis: 2). At 
study entry patients’ median (range) values of different 
scores were: symptoms (0-6): 1 (0-4); endoscopic (0-6): 
1 (0-6); neutrophils (0-3): 2 (0-3); acute histology (0-6): 
2 (0-6); chronic histology (0-6): 4 (1-6); PDAI (0-18): 5 
(1-15); mPDAI (0-12): 3 (0-10). Endoluminal calprotectin 
value was: 167.73 (6.50-1,125.0) mg/kg, median (range).
Measurement of calprotectin in the pouch endoluminal 
content shows similar sensitivity and specificity in pre-
dicting PDAI-defined pouchitis as calprotectin measure-
ment in feces.
We judged PDAI as gold standard for pouchitis eval-
uation. Accordingly, we started our analysis by assess-
ing the correlation between PDAI and calprotectin levels 
measured in the pouch endoluminal content. As shown in 
figure 1, the two variables were significantly correlated 
confirming previous data obtained with the measurement 
of fecal calprotectin (13). Moreover, ROC analysis for 
the calprotectin measurement in the pouch endoluminal 
content at two different cut-off values (66.2 and 37.6 mg/
kg) showed values of sensitivity (0.85 [0.57-0.98]; 0.92 
[0.63-0.99] [95% confidence interval, CI], respectively) 
and specificity (0.38 [0.20-0.59]; 0.19 [0.06-0.39] [95% 
CI], respectively) at predicting PDAI-defined pouchitis 
comparable to the values previously reported for fecal cal-
protectin (13). Similarly, area under curve (AUC) shows a 
good diagnostic accuracy of the test (AUC = 0.832 [0.68-
0.97] [95% CI]). Thus, measurement of calprotectin in the 
pouch endoluminal content, at least in this setting, gives 
results comparable to calprotectin measurement in feces. 
Pouch endoluminal calprotectin measurement effi-
ciently complements mPDAI in predicting PDAI defined 
pouchitis.
We then tested the ability of mPDAI in diagnosing pou-
chitis assessed with PDAI in our study’s population. We 
observed that while using PDAI 65% (26/40) and 35% 
(14/40) of our patients were defined as without or with 
pouchitis, respectively, using mPDAI the frequency was 
80% (32/40) and 20% (8/40), respectively. In particular, 7 
of the 14 patients (50%) as having pouchitis using PDAI 
would miss the diagnosis using mPDAI. This observation 
suggests that histological assessment of acute inflamma-
tion was not redundant, at least in our study’s population. 
Therefore, we evaluated the contribution of histology to 
PDAI. We observed a high correlation (Spearman r = 0.82, 
p < 0.0001, 95% CI: 0.67-0.90) between the acute his-
tologic subscore and PDAI as well as a relatively high 
dependence of PDAI on acute histologic subscore (r2 = 
0.6408, p < 0.0001, 95% CI: 0.31 to 0.51, by Pearson cor-
relation). This feature might well explain the differences 
observed in the present study between PDAI and mPDAI 
in the assessment of the presence of pouchitis. Since cal-
protectin is a protein abundantly expressed in neutrophils 
(17), we investigated the ability of calprotectin measure-
ment to reflect the histological subscore. We evaluated the 
differences of calprotectin concentration between patients 
with acute histological subscore ≥ 3 (n = 19) and patients 
with acute histological subscore < 3 (n = 21) as defined 
in PDAI. As shown in figure 2, we observed a significant 
difference in calprotectin concentration between the two 
groups of patients (486 [34-1,000], 70 [6.5-1,125] mg/kg, 
median [range], respectively; p = 0.0004, by Mann-Whit-
ney test), suggesting that calprotectin values may reflect 
the presence of histological inflammation. We performed 
a ROC analysis for the ability of calprotectin measurement 
to diagnose acute histological subscore ≥ 3. On the basis of 
the obtained results we fixed different range of calprotectin 
values corresponding to different values of sensitivity and 
specificity for the presence of inflammation to which we 
attributed a corresponding score ranging from 0-3. Spe-
cifically, we attributed score 0 to endoluminal calprotectin 
values < 37.625 that show sensitivity (%) 1 and 1speci-
ficity ranging from 1 to 0.762; score 1 to values ≥ 37.625 
and < 66.200 that show sensitivity (%) 0.947 and 1-spec-
ificity ranging from 0.762 to 0.524; score 2 to values ≥ 
66.200 and < 291.650 that show sensitivity (%) ranging 
from 0.895 to 0.737 and 1-specificity ranging from 0.524 
to 0.190; score 3 to values ≥ 291.650 that show sensitivity 
(%) 0.737 and 1-specificity 0.143.
We combined the calprotectin subscore in the mPDAI 
index obtaining the new Cal-mPDAI score detailed in table I. 
As shown in table II, the new Cal-mPDAI score shows 
values ranging from 0-15 with the illustrated frequency 
distribution of each value in our patients’ study group. As 
also shown in table II, values ≥ 7 identify only patients 
with pouchitis, suggesting value ≥ 7 as the cut-off value 
of the new score. The new score correlates with PDAI 
and shows a high dependency on it (r2 = 0.792, by Pearson 
correlation) (Fig. 3). 
Fig. 1. Correlation between the pouchitis disease activity index (PDAI) 
score and the levels of pouch endoluminal calprotectin. Spearman r = 
0.55, p = 0.0002, 95% CI: 0.28 to 0.74.
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We finally compared sensitivity, specificity, positive 
and negative predictive value of mPDAI and Cal-mPDAI 
in pouchitis diagnosis assessed with PDAI. As shown in 
table III, it appears that both sensitivity and specificity for 
pouchitis diagnosis were increased in Cal-mPDAI when 
compared with mPDAI, reaching the same specificity of 
PDAI. As a consequence, negative predictive value and 
positive predictive value of Cal-mPDAI values for diagno-
sis of pouchitis were both increased when compared with 
the values observed for mPDAI. 
DISCUSSION
This is a pilot study with a small number of patients 
enrolled according to very strict admission criteria to 
obtain a homogeneous population. Diagnosis of pouchitis 
was defined using PDAI, which was considered as gold 
standard for the diagnosis. Our results demonstrated that 
the new score (Cal-mPDAI) resulting from the combina-
tion of pouch endoluminal calprotectin measurement with 
the mPDAI is associated with an increased sensitivity and 
specificity for the diagnosis of pouchitis when compared 
with mPDAI-defined pouchitis. In particular, it is demon-
strated that the new score shows the same specificity as 
PDAI, which was assessed to be 96.2%, when compared 
to the physician and surgeon’s concomitant independent 
diagnosis of pouchitis (18). Since no symptoms and signs 
are unique to pouchitis, it is generally accepted that con-
current evaluation of endoscopic and histological findings 
brings to a more precise diagnosis that can be standard-
ized by the utilization of score system based indices (19). 
To date the PDAI score represents the more widely used 
index for the assessment of pouchitis. However, the delay 
in calculating PDAI score related to the histology com-
ponent represents a major obstacle for its application in 
daily practice. To overcome this limitation, the use of the 
mPDAI instead of PDAI has been proposed as an accept-
able compromise between the diagnostic accuracy and the 
inconvenient delay of diagnosis itself. Nevertheless, as 
shown in the present study, at least in our patients, this 
approach results in a significant proportion of patients 
with pouchitis missing the diagnosis showing that the 
exclusion of histological assessment from the score is 
inappropriate. In patients with IPAA, faecal calprotectin 
was shown to correlate with the histologic subscore (13), 
Fig. 2. Scatter plot showing distribution of the pouch endoluminal 
calprotectin values in patients with (subscore ≥ 3) and without (subscore 
< 3) histologically acute inflamed pouch.
Table I. The new Cal-mPDAI score range (0-15)  
and the subscores of each variable
Criteria Score
Clinical 
 Postoperative stool frequency
  Usual stool frequency
  1-2 stools/day more than postoperative usual





  None or rare
  Present daily
0
1
 Fecal urgency or abdominal cramp
  None
  Occasional




 Fever (temperature > 100 °F)
  Absent
















Endoluminal calprotectin values (mg/kg)
 < 37.6
 ≥ 37.6 < 66.2 
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suggesting that measurement of calprotectin may repre-
sent a potentially useful substitute for histology in the 
assessment of pouchitis. Clearly, histological evaluation 
remains mandatory to identify special features, such as 
granulomas, viral inclusion bodies, pyloric gland meta-
plasia and dysplasia (20).
In the present study, we observed that calprotectin 
measurement in pouch endoluminal fluid shows similar 
sensitivity and specificity in predicting pouchitis to the pre-
viously reported calprotectin measurement in feces (13), 
allowing us to use calprotectin values for further analysis. 
We observed a significant difference in the mean values of 
calprotectin in patients with histological subscore ≥ 3 when 
compared with patients with subscore < 3. On the basis 
of different values of sensitivity and specificity associat-
ed with histological subscore ≥ 3, we associated different 
range of calprotectin values with a subscore. The addition 
of this subscore to the mPDAI score resulted in a new score 
(Cal-mPDAI) showing specificity comparable to PDAI for 
the diagnosis of pouchitis and increased sensitivity when 
compared to mPDAI. The advantage of this approach is 
inherent to the fact that calprotectin measurement could 
be done during the same endoscopic session using the 
newly developed ELISA tests, which are easier and faster 
to be performed when compared to previous tests (21). 
Moreover, calprotectin measurement may reflect the global 
inflammatory activity of the pouch, possibly overcoming 
the disadvantage of histological examination related to the 
patchy expression of inflammation.
The main limitations of the present pilot study is the 
small number of patients enrolled according to very strict 
admission criteria to obtain an homogeneous population 
and that the new score still misdiagnosed 36% of patients 
with pouchitis. However this proportion is lower than the 
one observed using mPDAI score.
In conclusion, the present pilot study supports the idea 
that pouch endoluminal calprotectin measurement might 
improve the assessment of pouchitis activity made by 
mPDAI, resulting in a new index that, once validated in 
larger and less selected series of patients (i.e., including 
also other inflammatory conditions of the pouch), may be 
helpful in the management of patients with symptoms of 
suspected pouchitis.
Table II. Distribution of patients assessed with the new 
score (Cal-mPDAI) according to the presence or the 




n = patients Total
n = patients (40)
No (26) Yes (14)
0 2 0 2
1 0 0 0
2 3 0 3
3 7 1 8
4 7 1 8
5 4 0 4
6 3 3 6
7 0 2 2
8 0 3 3
9 0 1 1
10 0 0 0
11 0 2 2
12 0 0 0
13 0 1 1
14 0 0 0
15 0 0 0
Fig. 3. Correlation between the Cal-mPDAI score and PDAI. Spearman 
r = 0.88, p < 0.0001. 
Table III. Comparison between Cal-mPDAI and mPDAI in PDAI-defined pouchitis
Score Range Pouchitis cut-off SE (95% CI) SP (95% CI) PVP (95% CI) PVN (95% CI)
Cal-mPDAI 0-15 ≥ 7 64 (0.49-0.79) 100 (1) 100 (1) 83 (0.72-0.94)
mPDAI 0-12 ≥ 5 50 (0.35-0.65) 96 (0.36-1.56) 87 (0.77-0.87) 78 (0.65-0.91)
SE: Sensitivity; SP: Specificity; PVP: Predictive value of positive test; PVN: Predictive value of negative test; CI: Confidence interval.
Vol. 108, N.º 4, 2016 ENDOLUMINAL CALPROTECTIN MEASUREMENT IN ASSESSMENT OF POUCHITIS AND A NEW INDEX  195 
 OF DISEASE ACTIVITY: A PILOT STUDY
Rev esp enfeRm Dig 2016; 108 (4): 190-195
REFERENCES
1. Ståhlberg D, Gullberg K, Liljeqvist L, et al. Pouchitis following pel-
vic pouch operation forulcerative colitis: Incidence, cumulative risk, 
and risk factors. Dis Colon Rectum 1996;39:1012-8. DOI: 10.1007/
BF02054692
2. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis 
in patients after ileal pouch-anal anastomoses. World J Surg 2000;24: 
851-6. DOI: 10.1007/s002680010136
3. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proc-
tocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. 
Inflamm Bowel Dis 2008;14:20-8. DOI: 10.1002/ibd.20278
4. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: Defi-
nition, pathogenesis, and treatment. Gastroenterology 1994;107:1856-
60.
5. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchi-
tis. Gastroenterology 2003;124:1636-50. DOI: 10.1016/S0016-
5085(03)00325-1
6. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-
anal anastomosis: A Pouchitis Disease Activity Index. Mayo Clin Proc 
1994;69:409-15 DOI: 10.1016/S0025-6196(12)61634-6
7. Shen B. Pouchitis: What every gastroenterologist needs to know. 
Clin Gastroenterol Hepatol 2013;11:1538-49. DOI: 10.1016/j.cgh. 
2013.03.033
8. Shen B, Achkar JP, Connor JT, et al. Modified pouchitis disease activ-
ity index: A simplified approach to the diagnosis of pouchitis. Dis 
Colon Rectum 2003;46:748-53. DOI: 10.1007/s10350-004-6652-8
9. Kopylov U, Rosenfeld G, Bressler B, et al. Clinical utility of fecal 
biomarkers for the diagnosis and management of inflammatory bowel 
disease. Inflamm Bowel Dis 2014;20:742-56. DOI: 10.1097/01.MIB. 
0000442681.85545.31
10. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a sur-
rogate marker for endoscopic lesions in inflammatory bowel disease. 
Inflamm Bowel Dis 2012;18:2218-24. DOI: 10.1002/ibd.22917
11. Farkas K, Saródi Z, Bálint A, et al. The diagnostic value of a new fecal 
marker, matrix metalloprotease-9, in different types of inflammatory bow-
el diseases. J Crohns Colitis 2015;9:231-7. DOI: 10.1093/ecco-jcc/jjv005
12. Bonnín Tomàs A, Vila Vidal M, Rosell Camps A. Fecal calprotectin as 
a biomarker to distinguish between organic and functional gastrointes-
tinal disease. Rev Esp Enferm Dig 2007;99:689-93.
13. Johnson MW, Maestranzi S, Duffy AM, et al. Faecal calprotectin: A non-
invasive diagnostic tool and marker of severity in pouchitis. Eur J Gastro-
enterol Hepatol 2008;20:174-9. DOI: 10.1097/MEG. 0b013e3282f1c9a7
14. Yamamoto T, Shimoyama T, Bamba T, et al. Consecutive monitoring of 
fecal calprotectin and lactoferrin for the early diagnosis and prediction 
of pouchitis after restorative proctocolectomy for ulcerative colitis. Am 
J Gastroenterol 2015;110:881-7. DOI: 10.1038/ajg.2015.129
15. Shen, B. Acute and chronic pouchitis pathogenesis, diagnosis and treat-
ment. Nat Rev Gastroenterol Hepatol 2012;9:323-33.
16. Shepherd NA, Jass JR, Duval I, et al. Restorative proctocolectomy with 
ileal reservoir: Pathological and histochemical study of mucosal biopsy 
specimens. J Clin Pathol 1987;40:601-7. DOI: 10.1136/jcp.40.6.601
17. Røseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity 
in ulcerative colitis by faecal calprotectin, a novel granulocyte marker 
protein. Digestion 1997;58:176-80. DOI: 10.1159/000201441
18. Heuschen UA, Allemeyer EH, Hinz U, et al. Diagnosing pouchitis: 
Comparative validation of two scoring systems in routine follow-up. 
Dis Colon Rectum 2002;45:776-6. DOI: 10.1007/s10350-004-6297-7
19. Shen B, Achkar JP, Lashner BA, et al. Endoscopic and histologic eval-
uations together with symptom assessment are required for the diag-
nosis of pouchitis. Gastroenterology 2001;121:261-7. DOI: 10.1053/
gast.2001.26290
20. Kariv R, Plesec TP, Gaffney K, et al. Pyloric gland metaplasia and 
pouchitis in patients with ileal pouch-anal anastomoses. Aliment Phar-
macol Ther 2010;31:862-73. DOI: 10.1111/j.1365-2036.2010.04249.x
21. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six 
different calprotectin assays for the assessment of inflammatory 
bowel diseases. United European Gastroenterol J 2014;2:30-7. DOI: 
10.1177/2050640613518201
